SEC Form 4
Odyssey Therapeutics, Inc. (ODTX) insider trading
In the 12 months to Nov 19, 2026, one ODTX insider reported open-market sales of $32.0K across 1 filing; 7 insiders bought $75.3M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $32.0K
- 1 filing · 1 insider
- Open-market purchases
- $75.3M
- 7 filings
Who traded ODTX, and when
- Purchase
- Sale
ODTX daily close from May 8, 2026 to Nov 18, 2026, between $15.56 and $28.76, last $18.98. 1 sale and 7 purchase filings by 7 insiders, marked at their filing dates. Jon Winkelried, Other: bought $25.0M across 1 filing, first filed May 13, 2026, last May 13, 2026. Dimension Capital II, L.P., Director: bought $20.0M across 1 filing, first filed May 12, 2026, last May 12, 2026. Nan (LN) Li, Director: bought $20.0M across 1 filing, first filed May 11, 2026, last May 11, 2026. Simeon George, 10% owner: sold $32.0K and bought $10.0M across 2 filings, first filed May 11, 2026, last May 11, 2026. Shelley Chu, Director: bought $200.0K across 1 filing, first filed May 11, 2026, last May 11, 2026. Jeffrey M. Leiden, Director: bought $100.0K across 1 filing, first filed May 11, 2026, last May 11, 2026. Jason Haas, Chief Financial Officer: bought $20.0K across 1 filing, first filed May 11, 2026, last May 11, 2026.
Largest mark · tap a row for others
Jon Winkelried · Other
Purchase $25,000,002
1,388,889 shares at $18.00 avg
Filed May 13, 2026 · traded May 11
Close on filing date $17.94
Jon Winkelried · Other
Other
$25.0M boughtDimension Capital II, L.P. · Director
Director
$20.0M boughtNan (LN) Li · Director
Director
$20.0M boughtSimeon George · 10% owner
10% owner
$32.0K sold$10.0M boughtShelley Chu · Director
Director
$200.0K boughtJeffrey M. Leiden · Director
Director
$100.0K boughtJason Haas · Chief Financial Officer
Chief Financial Officer
$20.0K boughtOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Jon Winkelried | Other | — | $25.0M | 1 | — | |
| Dimension Capital II, L.P. | Director | — | $20.0M | 1 | — | |
| Nan (LN) Li | Director | — | $20.0M | 1 | — | |
| Simeon George | 10% owner | $32.0K | $10.0M | 2 | — | |
| Shelley Chu | Director | — | $200.0K | 1 | — | |
| Jeffrey M. Leiden | Director | — | $100.0K | 1 | — | |
| Jason Haas | Chief Financial Officer | — | $20.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jon Winkelried Other | Purchase | 1,388,889 | $18.00 | $25.0M | 3,690,146 | |
traded | Dimension Capital II, L.P. Director | Purchase | 1,111,111 | $18.00 | $20.0M | 3,333,516 | |
traded | Shelley Chu Director | Purchase | 11,111 | $18.00 | $200.0K | 11,111 | |
traded | Nan (LN) Li Director | Purchase | 1,111,111 | $18.00 | $20.0M | 3,333,516 | |
traded | Jason Haas Chief Financial Officer | Purchase | 1,000 | $20.00 | $20.0K | 62,908 | |
traded | Jeffrey M. Leiden Director | Purchase | 5,000 | $20.00 | $100.0K | 270,198 | |
traded | Simeon George 10% owner | Sale | 1,780 | $18.00 | $32.0K | Multiple accounts | |
traded | Simeon George 10% owner | Purchase | 555,555 | $18.00 | $10.0M | Multiple accounts |
GET /stocks/filings/vX/form-4?tickers=ODTX&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ODTX"
],
"issuer_cik": "0001882782",
"owner_cik": "0001366946",
"accession_number": "0001999371-26-010652",
"form_type": "4",
"filing_date": "2026-05-13",
"period_of_report": "2026-05-11",
"issuer_name": "Odyssey Therapeutics, Inc.",
"issuer_trading_symbol": "ODTX",
"owner_name": "WINKELRIED JON",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-05-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1388889,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3690146,
"transaction_value": 25000002,
"not_subject_to_section_16": true,
"direct_or_indirect": "I",
"nature_of_ownership": "See Explanation of Responses",
"footnotes": [
{
"id": "F5",
"description": "On May 11, 2026, in connection with the Issuer's initial public offering, TPG Orazio II acquired an aggregate of 1,388,889 shares of Common Stock at a price of $18.00 per share."
},
{
"id": "F1",
"description": "Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the \"Reporting Persons\"), which exercises direct or indirect control over entities that collectively hold 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG LSI GenPar Advisors, LLC, which is the general partner of TPG LSI GenPar, L.P., which is the sole member of TPG LSI SPV GP, LLC."
},
{
"id": "F2",
"description": "TPG LSI SPV GP, LLC is the general partner of each of (i) TPG LSI Rise Orazio, L.P. (\"TPG Orazio I\"), which directly holds 2,301,257 shares of Common Stock (\"Common Stock\") of Odyssey Therapeutics, Inc. (the \"Issuer\"), and (ii) TPG LSI Rise Orazio II, L.P. (\"TPG Orazio II\" and, together with TPG Orazio I, the \"TPG Funds\"), which directly holds 1,388,889 shares of Common Stock."
},
{
"id": "F6",
"description": "Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any."
},
{
"id": "F7",
"description": "Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests."
}
],
"remarks": "(8) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.\n(9) Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission."
},
{
"tickers": [
"ODTX"
],
"issuer_cik": "0001882782",
"owner_cik": "0001903793",
"accession_number": "0001999371-26-010652",
"form_type": "4",
"filing_date": "2026-05-13",
"period_of_report": "2026-05-11",
"issuer_name": "Odyssey Therapeutics, Inc.",
"issuer_trading_symbol": "ODTX",
"owner_name": "TPG GP A, LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-05-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1388889,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3690146,
"transaction_value": 25000002,
"not_subject_to_section_16": true,
"direct_or_indirect": "I",
"nature_of_ownership": "See Explanation of Responses",
"footnotes": [
{
"id": "F5",
"description": "On May 11, 2026, in connection with the Issuer's initial public offering, TPG Orazio II acquired an aggregate of 1,388,889 shares of Common Stock at a price of $18.00 per share."
},
{
"id": "F1",
"description": "Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the \"Reporting Persons\"), which exercises direct or indirect control over entities that collectively hold 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG LSI GenPar Advisors, LLC, which is the general partner of TPG LSI GenPar, L.P., which is the sole member of TPG LSI SPV GP, LLC."
},
{
"id": "F2",
"description": "TPG LSI SPV GP, LLC is the general partner of each of (i) TPG LSI Rise Orazio, L.P. (\"TPG Orazio I\"), which directly holds 2,301,257 shares of Common Stock (\"Common Stock\") of Odyssey Therapeutics, Inc. (the \"Issuer\"), and (ii) TPG LSI Rise Orazio II, L.P. (\"TPG Orazio II\" and, together with TPG Orazio I, the \"TPG Funds\"), which directly holds 1,388,889 shares of Common Stock."
},
{
"id": "F6",
"description": "Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any."
},
{
"id": "F7",
"description": "Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests."
}
],
"remarks": "(8) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.\n(9) Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 27 records
- Option exercises2 records
- Tax withholding2 records
- Other23 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
How current is ODTX’s insider data?
These are ODTX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ODTX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ODTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.